MiMedx Group, Inc (MDXG)

From the record

MiMedx Group, Inc's filings since 2017 show 19 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2019-02-25); a warning not to rely on past financial statements (8-K item 4.02, the latest 2018-06-07); an auditor change (8-K item 4.01, 4 times, the latest 2021-03-30); a late-report notice (Form NT 10-K or NT 10-Q, 10 times, the latest 2020-05-11) (its current reports).

From the record

MiMedx Group, Inc's 10 filed years say what it did: revenue went from $222 million in fiscal 2016 to $419 million in fiscal 2025, up 7.3% a year; it rose in 6 of 9 years; the deepest fall was 33% from fiscal 2018 to fiscal 2021; net income was positive in 5 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, MiMedx Group, Inc's diluted share count grew about 9.9% a year, and dividends and buybacks returned about 6% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, MiMedx Group, Inc earned about 19 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 101 cents per dollar of everything the company owns. Leverage: it owed about 25 cents per dollar of assets, and net share issuance: its share count grew 0.5% over the year (the filed statements).

From the record

MiMedx Group, Inc's standing among 109 graded names in its industry family: revenue of $419 million in fiscal 2025 ranks in the top 29% by size; a net margin of 11.6% ranks in the top 17%; revenue growth of 16% a year over the last 3 filed years ranks in the top 47% (its annual reports).

From the record

MiMedx Group, Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Capper, Joseph H (Chief Executive Officer, as filed), filing under that title since 2023-01-31, 3.8 years (bottom 44% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 3.8 years (bottom 21%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 12%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

MiMedx Group, Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $166 million against debt of $16 million leaves 43.7% of its assets as net cash, top 21% of its family; cash from operations less capital spending is 17.7% of revenue (top 11%); a gross margin of 82.6% (top 11%); research spending of 3.6% of revenue (bottom 16%) (its annual report).

From the record

MiMedx Group, Inc's growth drivers, from the filed years to fiscal 2025: revenue grew 16% a year over the last three filed years against 7.3% over all 10, speeding up (top 13% of its family); the newest year grew 20% (top 32%); research spending grew 5.9% a year (bottom 50%); capital spending grew -21.4% a year (bottom 26%) (its annual reports). MiMedx Group, Inc reported 2 product lines in fiscal 2025: Wound at $276 million (66%), Surgical at $142 million (34%); 2 of 2 grew against the year before (its annual report).

From the record

MiMedx Group, Inc's newest year against its own record: revenue of $419 million in fiscal 2025 came in 5.1% above the $398 million its prior three years' pace pointed to (top 23% of its family); net income of $49 million against a prior three-year average of $23 million (top 17%); a net margin of 11.6% against 6.3% before (bottom 41%) (its annual reports).